Know Cancer

or
forgot password

Pathogenesis of Acute Leukemia, Lymphoproliferative Disorders, and Myeloproliferative Disorders


N/A
1 Year
N/A
Open (Enrolling by invite only)
Both
Acute Leukemia, Lymphoproliferative Disorders, Myeloproliferative Disorders

Thank you

Trial Information

Pathogenesis of Acute Leukemia, Lymphoproliferative Disorders, and Myeloproliferative Disorders


Inclusion Criteria:



- Suspected or confirmed diagnosis of AL, LPD, MDS, or MPD

- Male or female of all ages

- Willing and able to sign informed consent

- Willing guardian consent for participants under 18 years of age

Exclusion Criteria:

- No suspected or confirmed diagnosis of acute leukemias (AL), lymphoproliferative
disorders (LPD), myelodysplastic syndromes (MDS), or myeloproliferative diseases
(MPD)

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

The frequency of activating mutations of tyrosine kinases, and phosphatases in patients with acute leukemias (AL), lymphoproliferative disorders(LPD), myelodysplastic syndromes(MDS), and myeloproliferative disease(MPD)

Outcome Time Frame:

Duration of the study; Up to 5 years

Safety Issue:

No

Authority:

United States: Institutional Review Board

Study ID:

IRB00004422

NCT ID:

NCT01728402

Start Date:

September 2008

Completion Date:

October 2013

Related Keywords:

  • Acute Leukemia
  • Lymphoproliferative Disorders
  • Myeloproliferative Disorders
  • Leukemia
  • Lymphoproliferative Disorders
  • Myeloproliferative Disorders
  • Acute Disease
  • Hematologic Neoplasms

Name

Location

OHSU Knight Cancer InstitutePortland, Oregon  97239